*EMBARGOED All research presented at the 2021 ACG Annual Scientific Meeting and Postgraduate Course is strictly embargoed until Sunday, October 24, 2021, at 3:30 pm EDT.
Oral 3 Humoral Immune Response After Completion of COVID-19 Vaccine Series Among Patients With IBD
Author Insight from Kimberly N. Weaver, MD, University of North Carolina Chapel Hill
What’s new here and important for clinicians?
The vast majority (95%) of IBD patients had detectable anti-receptor binding domain (anti-RBD) IgG antibodies after completing the two-part mRNA SARS-CoV-2 vaccine series. Most IBD medications do not prevent an initial antibody response after SARS-CoV-2 vaccination, unlike other classes of immune suppression such as B-cell depletion therapy. Additional data are forthcoming on a larger subset of participants in the PREVENT-COVID study which will allow for analysis of factors associated with humoral immune response and potential optimization of immunization strategies
What do patients need to know?
Most patients with IBD, including those on immunosuppressive medications, mount an initial response to the mRNA COVID-19 vaccine series. Individuals treated with systemic corticosteroids (i.e. prednisone) and/or combination therapy with an anti-TNF agent and immunomodulator may benefit from an additional dose of the COVID-19 vaccine.
Kimberly N. Weaver, MD, University of North Carolina Chapel Hill
kim_weaver [at] med [dot] unc [dot] edu
Media Interview Requests
To arrange an interview with any ACG experts or abstract authors, please contact Becky Abel of ACG via email at mediaonly [at] gi [dot] org.